Evaluating the potential usefulness of new prognostic and predictive indicators in node-negative breast cancer patients.
about
Predicting Clinical Outcomes Using Molecular BiomarkersClinical relevance of biologic factors in male breast cancer.Prognostic implications of expression of the cell cycle inhibitor protein p27Kip1.The relationship between prognostic and predictive factors in the management of breast cancer.Methodological challenges in the evaluation of prognostic factors in breast cancer.Assessing the clinical impact of prognostic factors: when is "statistically significant" clinically useful?Routinely available indicators of prognosis in breast cancer.A multiplexed screening method for agonists and antagonists of the estrogen receptor protein.Predictive markers in primary breast cancer compared with lymph node and bloodspread metastases.Mortality risk of black women and white women with invasive breast cancer by hormone receptors, HER2, and p53 statusThe prognostic significance of determining DNA content in breast cancer by DNA image cytometry: the role of high grade aneuploidy in node negative breast cancer.Relationship of PS2 with response to tamoxifen therapy in patients with recurrent breast cancer.Differential expression of the topoisomerase II alpha and beta genes in human breast cancers.REporting recommendations for tumour MARKer prognostic studies (REMARK)Does vascular endothelial growth factor (VEGF) predict local relapse and survival in radiotherapy-treated node-negative breast cancer?Enhanced prediction of breast cancer prognosis by evaluating expression of p53 and prostate-specific antigen in combination.Application of an original RT-PCR-ELISA multiplex assay for MDR1 and MRP, along with p53 determination in node-positive breast cancer patientsBiomarkers and outcome after tamoxifen treatment in node-positive breast cancers from elderly women.The prognostic value of vascular endothelial growth factor in 574 node-negative breast cancer patients who did not receive adjuvant systemic therapy.Recent advances in the treatment of breast cancer.Flow cytometric DNA hypertetraploidy is associated with unfavourable prognostic features in breast cancer.Short-term significance of DNA ploidy and cell proliferation in breast carcinoma: a multivariate analysis of prognostic markers in a series of 308 patients.Novel molecular prognostic markers in breast cancer.The effect of docetaxel on developing oedema in patients with breast cancer: a systematic review.CYP2D6 genotype is not associated with survival in breast cancer patients treated with tamoxifen: results from a population-based study.Retrospective evaluation of premenopausal hormone-sensitive breast cancer patients treated with adjuvant gonadotropin-releasing hormone analogue: Anatolian Society of Medical Oncology (ASMO) study.Prostate-specific antigen induction by a steroid hormone in T47D cells growing in SCID mice.Regulation of BMI1 Polycomb gene expression in histological grades of invasive ductal breast carcinomas and its correlation with hormone receptor status.Statistical aspects of prognostic factor studies in oncology.Early distant relapse in "node-negative" breast cancer patients is not predicted by occult axillary lymph node metastases, but by the features of the primary tumour.FDG PET studies during treatment: prediction of therapy outcome in head and neck squamous cell carcinoma.p34cdc2 in invasive breast cancer: relationship to DNA content, Ki67 index and c-erbB-2 expression.Comparative study of the immunohistochemical phenotype in breast cancer and its lymph node metastatic location.Influence of investigator experience and microscopic field size on microvessel density in node-negative breast carcinoma.Side effects of adjuvant chemotherapy: perceptions of node-negative breast cancer patients.Association of angiogenesis and poor prognosis in node-positive patients receiving anthracycline-based adjuvant chemotherapy.Identification of clinically useful cancer prognostic factors: what are we missing?HER-2 protein overexpressing breast cancer without gene amplification shows higher hormone receptor expression than HER-2 protein overexpressing breast cancer with gene amplification.Association of Angiogenesis in Lymph Node Metastases With Outcome of Breast Cancer
P2860
Q26747424-56898EE4-38B7-47B5-A934-46A9AB1492BBQ33183149-45D932FE-BF68-4CF6-90BD-82FB50893CE2Q33538422-4F665FD0-C9EF-4EEF-9D3E-E5257499A276Q33538455-25849BF6-4C60-4E83-8EBA-231A26F2D5DAQ33538459-EE1408E7-DD5E-4AD9-9D8E-7EC11951244DQ33538461-26B7F220-BE0E-42DE-A68A-B6F1724C1698Q33539150-AB35AACA-0581-4D06-93E8-91261CF33619Q34210078-3429A0F3-3DE4-42C7-87C5-EA08E1C0ADB4Q34582099-98CF33DA-F649-41AA-9C37-3F1EF861F34DQ34705321-D4802F2E-1B75-4B73-88E3-8D765E11E3AAQ35954421-14A128D3-F6AE-4FF2-86E7-C4D5547B8457Q36080684-28001DC0-6A3E-4B61-848B-F8770C05C530Q36135365-C70F15D2-C5C3-4913-8DF6-EA4B193AE821Q36615178-30884850-84DC-4E3A-A509-682D3CC41C50Q36619696-03B921E6-3584-4EE6-81A4-CBB839B50B0BQ36619873-50A6C725-E6DC-45D1-9575-BE91BB2B544CQ36620717-AC72E82E-752E-4D53-BD6F-BBBA44B3224EQ36621098-57E02A9F-4D11-4DF0-BA18-0A7CE56AED6DQ36624140-041C0385-410C-4787-9FA8-2705479AC681Q36679529-AAAFFD85-2053-4C2E-A2E2-BBBE0AFC394AQ37209971-D178A6A4-E10A-4084-BF90-8A4C6DD098A5Q37228342-2B6485ED-0FD1-4395-8550-1152F65062E0Q38089820-694D0557-C8B7-4AB8-ACB4-48A9289B2339Q38263087-5FE2B8B1-CB5D-449E-AA13-A43FC17606FFQ38668766-98F869DE-8076-45C9-983B-1523C62FF301Q38692427-D0265E38-6E1E-4F99-95E6-0A8D35E61CB5Q41051526-22053309-B4C8-46FD-9EAC-6DD2C466DBFBQ42282470-1E8F73B2-10A8-45AF-8933-153D9C886824Q42388377-19310082-C811-4FD7-B4C6-98DBCBCC081DQ43557996-4DABB082-1069-4AEF-86FF-9C6D7AF34191Q43916705-C2C8053F-DC16-429F-815D-DB5E198566E7Q44840763-CEC1E850-3617-4BCD-8FA3-A9DC9E0FA977Q44938517-7243715D-5A60-4B8E-98D1-126E0B96E0F3Q47317744-574B1710-510C-4010-AC15-D516FDEC0095Q51102883-AE855ACF-296C-492B-A72C-945B86A92A5EQ52207131-BCC1CED2-081A-45EA-8092-1A1D90DCD71EQ52979961-7897C5A7-83C9-43E2-B922-5639692FA33BQ54727540-042850EC-A90D-4291-A5BA-BB77D7B8676CQ57578640-B9FF21B4-828A-457A-BDAD-0F0A12A2BCAD
P2860
Evaluating the potential usefulness of new prognostic and predictive indicators in node-negative breast cancer patients.
description
1993 nî lūn-bûn
@nan
1993年の論文
@ja
1993年学术文章
@wuu
1993年学术文章
@zh-cn
1993年学术文章
@zh-hans
1993年学术文章
@zh-my
1993年学术文章
@zh-sg
1993年學術文章
@yue
1993年學術文章
@zh
1993年學術文章
@zh-hant
name
Evaluating the potential usefu ...... gative breast cancer patients.
@en
type
label
Evaluating the potential usefu ...... gative breast cancer patients.
@en
prefLabel
Evaluating the potential usefu ...... gative breast cancer patients.
@en
P2093
P356
P1476
Evaluating the potential usefu ...... gative breast cancer patients.
@en
P2093
P304
P356
10.1093/JNCI/85.15.1206
P407
P577
1993-08-01T00:00:00Z